Latest Conference Articles

December 10th 2016, 5:05am

San Antonio Breast Cancer Symposium

The combination of pembrolizumab and eribulin demonstrated a 33.3% objective response rate for patients with metastatic triple-negative breast cancer who received 0 to 2 prior lines of therapy.

December 10th 2016, 3:31am

San Antonio Breast Cancer Symposium

The artificial intelligence computer program Watson for Oncology (WFO) achieved a high degree of concordance with tumor board recommendations in a double-blinded validation study in Bengaluru, India, according to results presented at the 2016 San Antonio Breast Cancer Symposium (SABCS).

December 10th 2016, 3:16am

San Antonio Breast Cancer Symposium

Aromatase inhibitor (AI) therapy may pose a risk of cardiovascular disease to postmenopausal women with early-stage breast cancer, raising the possibility of a long-term complication in an era of growing survivorship when patients are treated with estrogen-targeting drugs for years.

December 10th 2016, 1:50am

San Antonio Breast Cancer Symposium

Women who are experiencing symptoms of menopause are less likely to adhere to treatment, according to findings presented at the 2016 San Antonio Breast Cancer Symposium.

December 10th 2016, 1:49am

San Antonio Breast Cancer Symposium

A subgroup analysis of the randomized MONALEESA-2 trial showed that patients with advanced HR-positive, HER2-negative breast cancer, and visceral metastases obtained a significant benefit from treatment with the CDK4/6 inhibitor ribociclib combined with letrozole.

December 10th 2016, 12:12am

San Antonio Breast Cancer Symposium

Treatment with sacituzumab govitecan was well-tolerated and induced durable responses, some lasting longer than 1 year, for heavily pretreated patients with metastatic triple-negative breast cancer.

December 9th 2016, 11:33pm

San Antonio Breast Cancer Symposium

Findings from the first prospective, randomized clinical trial to evaluate modern scalp-cooling demonstrate that the system is safe and effective in reducing hair loss in women being treated with chemotherapy for their breast cancer, especially for those on taxane-based regimens.

December 9th 2016, 5:02am

San Antonio Breast Cancer Symposium

​Sara A. Hurvitz, MD, medical oncologist, associate professor of Medicine, medical director, Jonsson Comprehensive Cancer Center Clinical Research Unit, UCLA, discusses the findings of the neoMONARCH trial, a neoadjuvant regimen combining the CDK4/6 inhibitor abemaciclib with anastrozole, which induced a response rate of 54.7% in patients with hormone receptor–positive, HER2-negative early-stage breast cancer.

December 9th 2016, 4:41am

San Antonio Breast Cancer Symposium

John Robertson, MD, professor of Surgery, University of Nottingham, Royal Derby Hospital Centre, United Kingdom, discusses a subgroup analysis of the FALCON trial, which compared treatment with fulvestrant (Faslodex) versus anastrozole (Arimidex) in patients with HR-positive advanced breast cancer.

December 9th 2016, 4:14am

San Antonio Breast Cancer Symposium

An attempt to strengthen neoadjuvant treatment of patients with locally advanced HR-positive and HER2-positive breast cancer by adding estrogen deprivation therapy to a standard regimen failed to significantly improve response rates but did illustrate the extensive toxicity of the chemotherapy agents used in this setting.

December 9th 2016, 3:38am

San Antonio Breast Cancer Symposium

A biomarker analysis of participants in a phase II breast cancer trial demonstrated potential for identifying tumor markers to predict susceptibility to specific therapies.

December 9th 2016, 1:28am

San Antonio Breast Cancer Symposium

Adjuvant ibandronate (Boniva) added to hormone therapy did not provide a clinical benefit to postmenopausal patients with HR-positive, early-stage breast cancer, according to findings from the phase III TEAM IIB trial.

December 9th 2016, 1:12am

San Antonio Breast Cancer Symposium

A neoadjuvant regimen combining the CDK4/6 inhibitor abemaciclib with anastrozole induced a response rate of 54.7% in patients with HR+/HER2-negative early-stage breast cancer, according to findings from the phase II neoMONARCH trial.

December 8th 2016, 11:09pm

IASLC World Conference on Lung Cancer

Determination of the PD-L1 status of a patient’s tumor has become increasingly important for informing the clinical decision whether to offer certain immunotherapeutic agents, making standardization of the tests and antibodies used to determine the PD-L1 status necessary to provide accurate and consistent results.

December 8th 2016, 10:17pm

San Antonio Breast Cancer Symposium

Median progression-free survival was improved by 2.1 months with the addition of the pan-PI3K inhibitor buparlisib to fulvestrant for women with HR-positive/HER2-negative advanced breast cancer who received a prior aromatase inhibitor and progressed on or after an mTOR inhibitor.

December 8th 2016, 7:42am

ASH Annual Meeting and Exposition

According to the results of the phase III StaMINA trial evaluating posttransplant therapy in multiple myeloma, a second a round of chemotherapy or stem cell transplant does not improve progression-free survival or overall survival compared with the current standard course of treatment alone.

December 8th 2016, 7:11am

ASH Annual Meeting and Exposition

Early data from a phase I/II study suggest that the combination of brentuximab vedotin (Adcetris) and nivolumab (Opdivo) may be an active and well-tolerated outpatient regimen in patients with relapsed/refractory classical Hodgkin lymphoma after failure of standard frontline chemotherapy.

December 8th 2016, 5:36am

San Antonio Breast Cancer Symposium

Geoffrey Lindeman, MD, joint head, Stem Cells and Cancer Division at The Walter and Eliza Hall Institute of Medical Research, discusses a study exploring RANK ligand as a target for breast cancer prevention in patients who harbor the BRCA1 mutation.

December 8th 2016, 5:14am

San Antonio Breast Cancer Symposium

Noah S. Kornblum, MD, assistant professor of medicine, Albert Einstein College of Medicine, and attending physician of medicine, Montefiore-Einstein Center for Cancer Care, discusses the phase II PrECOG 0102 trial, which explored the addition of everolimus (Afinitor) to fulvestrant (Faslodex) as a treatment for patients with metastatic hormone receptor (HR)–positive, HER2-negative breast cancer.

December 8th 2016, 4:04am

San Antonio Breast Cancer Symposium

First results from the phase III DATA study show no advantage to extending anastrozole therapy from 3 years to 6 for the primary endpoint of 5-year adapted disease-free survival.